In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...

We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...

Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies.

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...

European shares closed lower on Thursday, with defence and industrial stocks leading losses, after data showed U.S. inflation ...

Shares of the UK-based pharma giant GlaxoSmithKline PLC ($GB:GSK) soared over 6% after the company announced a settlement of ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

GSK shares top the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn ...

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...

Pharmaceutical giant GSK will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac ...